In case you missed it9 Apr 2019 13:15
RNS RNS RNS!!
NFX today announces it has signed an agreement for cannabinoid therapeutics development, licensing and commercialisation containing up to £51 million of upfront, R&D and milestone payments, plus long-term royalties of 20% of net sales (the "Agreement").
Ebers Tech Inc. (Ebers) is a private Canadian company backed by leaders from the financial sector with connections to major vertically integrated US market-facing cannabinoid players. The Agreement enables Ebers to employ Nuformix's technology platforms to bring a range of superior, differentiated therapeutic cannabinoid products to market for a multitude of consumer product and pharmaceutical applications.
Under the terms of the Agreement and the expected development timeline, Nuformix will receive a significant upfront payment and believes it will earn further R&D and early-stage milestone payments